Francisco Lopez-Jimenez, Roderick H. Cushman Professor of Cardiovascular Sciences Mayo Clinic Alix School of Medicine; Co-Director, Artificial Intelligence in Cardiology.Editor-In-Chief, Mayo Clinic Proceedings: Digital Health Consultant, Department of CVD, Mayo Clinic

Dr. Lopez-Jimenez is the Roderick H. Cushman Professor of Cardiovascular Sciences at Mayo Clinic Alix School of Medicine, the past Chair of the Division of Preventive Cardiology, the Co-Director of Artificial Intelligence in Cardiology in the Department of Cardiovascular Medicine at Mayo Clinic, Rochester. He is the Editor-In-Chief of Mayo Clinic Proceedings: Digital Health. Dr. Lopez-Jimenez did his cardiology fellowship at Mount Sinai Medical Center in Miami, Florida and at Brigham and Women’s Hospital, Harvard Medical School. He holds a Master of Science degree from Harvard School of Public Health and a MBA degree from Augsburg University. His primary research interest focuses on the use of artificial intelligence and digital health in cardiovascular medicine. He has also studied the intersection between obesity, metabolic dysregulation and cardiovascular diseases. Dr. Lopez-Jimenez has published more than 500 scientific publications and book chapters, including being a co-editor of the only book in Artificial intelligence in Cardiovascular Medicine. He chaired the 2025 World Heart Federation Annual Report, focused on obesity and cardiovascular diseases. He leads the Cross-Sectional Working Group in AI, for the American College of Cardiology. His scientific work has been cited more than 20,000 times and has given lectures in 28 different countries.
Financial relationships
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:AnumanaTopic:Member of the scientific advisory boardDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Novo NordiskTopic:Member of the scientific advisory boardDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:IonisTopic:Member of the scientific advisory boardDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:New AmsterdamTopic:Member of the scientific advisory boardDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Kento HealthTopic:Member of the scientific advisory boardDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:WizehealthTopic:Member of the scientific advisory boardDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:RegeneronDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:NovartisDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:MediwhaleDate added:04/15/2026Date updated:04/15/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:ResMedDate added:04/15/2026Date updated:04/15/2026

Facebook
X
LinkedIn
Forward